Marker-Free E. coli Strains for Antimalarial Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bacterial surrogate models for antimalarial drug screening are inadequate for testing combination drugs targeting both dihydrofolate reductase-thymidylate synthase (DHFR-TS) and 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase-dihydropteroate synthase (HPPK-DHPS) enzyme activities, as they lack the capacity to simultaneously assess both types of drugs and are hindered by the presence of antibiotic resistance markers, limiting the introduction of multiple plasmids and recombinant DNA vectors.
Innovation Solution
Development of marker-free Escherichia coli strains with sequential disruptions of thyA, folA, folK, and folP genes, allowing for the introduction of plasmids bearing complementing parasite genes and enabling the testing of single and combination drugs inhibiting up to four enzyme targets in the folate biosynthesis pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic resistance markers are used to establish gene knockouts in E. coli, then the cell can be selected and maintained, but the capacity to introduce multiple plasmids and recombinant DNA vectors is limited
Solution Approach 1:
The invention removes antibiotic resistance markers from the E. coli genome after gene knockout is achieved. By extracting these markers, the system maintains the ability to select and maintain knockout cells during the process, but eliminates the limitation they impose on introducing multiple plasmids later. This allows the bacterial surrogate model to be used for testing combination drugs without the constraint of antibiotic marker availability.
2Measurement precision
If conventional in vitro antimalarial screening assay using malaria parasites is used, then accurate evaluation of drug efficacy is achieved, but the process is labor intensive, expensive, and requires specialized personnel and equipment
Solution Approach 1:
The invention creates a bacterial surrogate model that copies the essential functional elements needed for drug screening. Instead of using actual malaria parasites, the system uses E. coli with disrupted folate pathway genes complemented by parasite gene plasmids. This copy preserves the ability to evaluate drug efficacy against parasite targets while eliminating the need for complex parasite culture systems, specialized equipment, and highly trained personnel.
Solution Approach 2:
The invention changes the biological system parameter from eukaryotic malaria parasites to prokaryotic E. coli. This parameter change maintains the functional capability to screen for antifolate drugs while dramatically simplifying the experimental system. The bacterial system grows faster, requires simpler media, and can be handled by personnel with basic microbiology training, thus reducing device complexity and operational requirements while preserving measurement precision for drug efficacy evaluation.
3Adaptability or versatility
If multiple gene knockouts are performed in E. coli to create a comprehensive surrogate model, then the ability to test combination drugs is improved, but the complexity of constructing the model increases
Solution Approach 1:
The invention segments the gene knockout process into discrete, manageable steps. Each folate pathway gene (folA, folP, folK, thyA) is knocked out separately using individual plasmids with specific antibiotic resistance markers. This segmentation allows systematic construction of the multi-knockout strain while maintaining clear selection criteria at each step. The modular approach reduces overall complexity by breaking down a complex multi-gene modification task into simpler, sequential operations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting bacterial model allows for consistent antifolate screening results comparable to conventional methods, facilitating high-throughput screening of antimalarial and parasitic disease treatments in laboratories with bacterial culture facilities, and demonstrating synergistic effects of drug combinations like pyrimethamine and sulfathiazole.
Implementation Method 1
Transformation of pKD46 Plasmid into Escherichia coli BL21(DE3) Using Heat Shock Method... Construction of Plasmids Used for Disrupting Target Genes... Introduction of Linear Targeting DNA into E. coli BL21(DE3) by Electroporation... Red recombinase assisted recombination
Implementation Method 2
Transformation of pCP20 plasmid for expressing FLP recombinase... Cells were cultured at 30 degrees Celsius for 3 hours to allow FLP recombinase enzyme to express and remove the antibiotic resistance gene
Implementation Method 3
Transformation of pKD46 Plasmid into Escherichia coli BL21(DE3) Using Heat Shock Method... Transformation of pCP20 plasmid for expressing FLP recombinase by the heat shock method
Implementation Method 4
Introduction of Linear Targeting DNA into E. coli BL21(DE3) by Electroporation
Implementation Method 5
Construction of marker-free single thyA KO, folA KO, folP KO, or folK KO or Multiple Gene Knockout E. coli Strains... thyA (thymidylate synthase), and/or folA (dihydroiolate reductase), and/or folP (dihydropteroate synthase), and/or folK (7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase)
Implementation Method 6
Two important enzymes in the folate biosynthesis pathway, namely dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), are targets of sulfa drugs (anti-DHPS) and anti-DHFR antifolates (pyrimethamine, cycloguanil, and WR99210) respectively... Anti-DHPS drugs and anti-DHFR drugs are synergistic
Data Source
AI summary
In this invention, cell lines are created for enzyme inhibitory testing of inhibitors against Plasmodium falciparum DHFR-TS and HPPK-DHPS. Provided the complementing DHFR-TS and HPPK-DHPS have sufficient activities to support growth of the surrogates in un-supplemented medium, the same surrogates could be used for screening inhibitors of targets against other parasite and pathogen species e.g. Plasmodium vivax, Trypanosoma brucei, Trypanosoma cruzi, Toxoplasma gondii or Mycobacterium tuberculosis. The cell lines in this invention are Escherichia coli strain whose thyA, folA, folK, and folP genes were disrupted using genetic knockout coupled with elimination of antibiotic resistance markers. The thyA KO, folP KO, folK KO, thyAfolA KO, folKfolP KO, thyAfolAfolP KO, thyAfolAfolK KO and thyAfolAfolKfolP KO E. coli cell lines are easy and convenient for testing single and combination drugs as plasmids bearing complementing parasite genes can be introduced simply by transformation using standard antibiotic selection.